
RVTY Stock: Growth, Valuation and Risks
Revvity’s latest reported quarter beat the provided EPS estimate, while reported revenue growth remains modest and its trailing P/E is elevated. A Friday investor-day event and conflicting analyst target datasets add context, but the evidence points to a mixed outlook rather than a clear direction.
Executive Summary
Investment Thesis: Revvity combines life-sciences tools and diagnostics businesses, with recent data showing 4.3% revenue growth, 37.8% earnings growth, and a reported November 3 EPS beat. Those positives sit alongside a 68.31 trailing P/E, 3.50% ROE, and a provided analyst target mean below the latest close. The November 13 Investor Day may give investors more detail on strategy, but the supplied news summary does not include new financial targets.
Current Price: $154.39 as of Friday, November 13 | Key Metric: 68.31 trailing P/E | Stance: NEUTRAL
U.S. markets are closed Saturday, November 14. The price and one-day change in this report refer to Friday’s close, not Saturday trading. The $154.39 price was down $2.63, or 1.67%, from the supplied previous close of $157.02.
Company Overview
Revvity, Inc. develops technologies and services used in life-sciences research and clinical diagnostics. Its tools and workflows support areas such as biological research, laboratory analysis, and testing, serving pharmaceutical, biotechnology, academic, and healthcare customers.
Key Products & Competitive Position
- Core Business: Life Sciences and Diagnostics solutions, with products and services used by research laboratories and healthcare organizations.
- Key Products: The portfolio includes laboratory instruments, reagents and consumables, diagnostic testing products, and software or services supporting scientific and clinical workflows.
- Competitive Moat: Specialized expertise, established customer relationships, and the ability to integrate instruments, consumables, and services can support recurring demand. The available information does not quantify a proprietary market-share advantage.
Recent Developments
Revvity hosted its 2026 Investor Day on Friday, November 13, with the announced theme of powering scientific intelligence through its Life Sciences and Diagnostics portfolio. The supplied announcement describes the event’s focus but does not provide specific new guidance, financial targets, or product launch details. Investors may look to the company’s event materials for those details rather than infer a change in outlook from the headline alone.
Financial Snapshot
Revenue & Earnings Trends
Yahoo Finance data included in the research shows trailing revenue of approximately $2.94 billion, up 4.3%, and earnings growth of 37.8%. It also reports $252.8 million of net income and $903.3 million of EBITDA. These figures suggest earnings have grown faster than sales, but the supplied snapshot does not explain the drivers, such as cost changes, portfolio mix, or one-time items, so the growth rate should not automatically be treated as a steady run rate.
For the quarter reported November 3, 2026, EPS was $1.38 versus the supplied $1.30 estimate, a $0.08, or roughly 6.2%, beat. The beat is a positive data point, but a single quarter does not establish a consistent earnings trend. The listed next earnings date is February 1, 2027, with an EPS estimate of $1.61.
Balance Sheet Highlights
The current ratio of 2.65 and quick ratio of 1.83 indicate that reported short-term assets exceed short-term liabilities by a useful margin. The data show approximately $592.8 million in cash against $2.77 billion of debt, implying net debt near $2.17 billion. Compared with reported EBITDA of about $903 million, that is roughly 2.4 times net debt to EBITDA, a level that makes cash generation and debt management worth monitoring.
Reported free cash flow was approximately $632.5 million and operating cash flow was $655.8 million. These figures are supportive of the company’s ability to fund operations, although the supplied snapshot does not provide a cash-flow history or the details needed to assess how repeatable that conversion is.
Valuation Analysis
Current Valuation Metrics
The forward P/E, PEG, and EV/EBITDA figures come from the supplied Yahoo Finance extract and may differ by calculation date or methodology from other providers. The P/S figure is calculated from the supplied $17.24 billion market capitalization and approximately $2.94 billion of trailing revenue. The 68.31 trailing P/E is high relative to the reported $2.27 TTM EPS, while the lower forward multiple depends on the accuracy of forecast earnings.
Historical Comparison
A reliable five-year average for the valuation multiples was not included in the available data, so a precise historical premium or discount cannot be stated. The supplied two-year price history reports an average close of $106.01 and a $154.39 latest price, but stock-price averages are not a substitute for comparing valuation against earnings and cash flow over time. The stock’s 52-week gain is substantial relative to its low, while the current price remains below its 52-week high.
Fair Value Estimate
The provided analyst-target set lists a mean of $146.43, about 5.2% below the Friday close, with a range of $115 to $185. A separate Yahoo Finance extract gives a different mean of $171.07 and a $122 to $200 range. Those datasets appear to use different analyst counts or collection dates, so neither should be treated as a precise standalone fair-value measure. A defensible independent DCF estimate cannot be produced from the supplied information because multi-year forecasts, discount-rate assumptions, and normalized cash flows are absent.
Competitive Landscape
Market Position
Market Share: Not quantified in the supplied data | Ranking: No verified industry ranking supplied
Revvity operates across specialized life-sciences research and diagnostic markets. Its competitive position depends on product performance, regulatory and quality requirements, installed laboratory workflows, customer service, and the ability to maintain demand for recurring reagents and consumables. A single consolidated market-share figure would be misleading because the company participates in multiple product categories.
Key Competitors
Competitive Advantages
- Specialized Portfolio: A combination of life-sciences and diagnostic offerings can serve customers across research and clinical settings.
- Workflow Integration: Instruments, consumables, and related services can become embedded in laboratory processes, which may support repeat business and switching costs.
- Customer and Technical Expertise: Established relationships and application knowledge can matter in regulated or technically demanding markets, although the supplied data do not quantify the resulting retention or pricing power.
Earnings Track Record
Last 4 Quarters: 1 confirmed beat / 0 confirmed misses, with 3 quarter outcomes not provided
Recent Earnings History
Guidance Trend
The supplied material includes an EPS estimate of $1.61 for the expected February 1, 2027 report, but it does not include management guidance revisions or a full-year outlook. The November 3 beat therefore provides evidence of quarterly execution, not confirmation that forecasts have been raised. At the next report, you can compare reported revenue, adjusted EPS, and management’s commentary with both prior guidance and consensus estimates.
Analyst Sentiment
Consensus Rating:
The supplied recommendation breakdown covers 18 analysts and leans toward Hold, with six Buy ratings and one Strong Sell. A separate finance-data extract reports 15 analyst opinions and a Buy consensus key, illustrating that provider coverage and update timing differ. These labels are third-party views, not a guarantee of future returns.
Price Targets
- Low: $115 in the supplied analyst-target set; a separate extract reports $122
- Mean: $146.43, or -5.2% versus $154.39; the separate extract reports $171.07
- High: $185 in the supplied analyst-target set; a separate extract reports $200
Recent Analyst Actions
No named recent analyst upgrades, downgrades, or target changes were included in the supplied information. The target discrepancy is material: one dataset implies modest downside from the Friday close, while the other implies upside. Readers comparing analyst forecasts should check the publication date, analyst count, and whether each target set reflects the same reporting period.
Recent News & Catalysts
Key Developments
- 2026 Investor Day: Revvity’s November 13 event focused on its Life Sciences and Diagnostics portfolio and the company’s stated scientific-intelligence strategy. Specific incremental forecasts were not included in the supplied announcement.
- Latest EPS Report: The November 3 report showed EPS of $1.38 against a $1.30 estimate, a modest positive surprise based on the figures provided.
- Sector Comparison Coverage: A November 11 Zacks article compared $RVTY with Elevance Health, though the supplied excerpt does not provide a detailed conclusion or a company-specific catalyst.
Upcoming Catalysts
Next Earnings: Expected February 1, 2027, EPS estimate $1.61 | Key Events: Investor Day follow-up materials, company guidance, revenue trends, and evidence that earnings growth is translating into durable cash generation
The next reported quarter is the clearest scheduled company-specific catalyst in the supplied calendar. No other dated regulatory, product, or corporate events were provided.
Technical Outlook
Current Price: $154.39 as of Friday, November 13 vs 52-Week High: $171.74 (-10.1% from high)
Trend Analysis
The price is approximately 90% above the $81.22 52-week low, but it is also about 10% below the 52-week high. Friday’s 1.67% decline and the $151.06 to $160.24 session range show short-term trading pressure, but the supplied information does not include moving averages, volume context, or momentum indicators. The available numbers alone are not enough to confirm a trend reversal or continuation.
Key Levels
- Resistance: Around $160.24, the supplied Friday session high, then $171.74, the 52-week high
- Support: Around $151, near Friday’s session low, then $140 as a round-number reference; analyst targets at $122 and $115 are broader valuation scenarios, not established technical support
Bull vs Bear Case
Bull Case
- Earnings Execution: The latest reported EPS exceeded the supplied estimate, while reported earnings growth is stronger than revenue growth.
- Cash Generation: Approximately $632.5 million of trailing free cash flow could support investment and debt service if that level proves durable.
- Forecast Earnings: The 25.92 forward P/E is materially below the trailing P/E, indicating that valuation depends on forecast EPS growth being delivered.
Bull Scenario Reference: $185, the high end of the supplied analyst-target set, about 19.8% above the Friday close. This is an analyst scenario, not a forecast.
Bear Case
- Valuation Sensitivity: A 68.31 trailing P/E leaves the share price sensitive to any shortfall in earnings expectations.
- Modest Sales Growth: Reported revenue growth of 4.3% may constrain the durability of faster earnings growth if margins or costs stop helping.
- Leverage and Returns: Net debt is approximately $2.17 billion and ROE is about 3.5%, leaving room for questions about capital efficiency and balance-sheet flexibility.
Bear Scenario Reference: $115, the low end of the supplied analyst-target set, about 25.5% below the Friday close. This is an analyst scenario, not a forecast.
Risks to Consider
- Valuation Risk: The elevated trailing multiple depends on expected earnings growth. If forecasts fall or earnings growth slows, the market could assign a lower multiple even if revenue remains positive.
- Competitive Risk: Larger suppliers such as $TMO and $DHR, as well as specialist companies, compete for laboratory budgets and diagnostic workflows. Pricing pressure or product displacement could affect growth and margins.
- Macro Risk: Research funding, pharmaceutical and biotechnology spending, healthcare budgets, and foreign-exchange movements can influence demand across the company’s customer base.
- Execution Risk: The company must convert its strategy into sustained sales and earnings while managing a portfolio spanning different end markets. The supplied Investor Day headline alone does not establish execution progress.
- Data Risk: Analyst target datasets conflict, and historical quarterly results were not supplied for three of the last four quarters. This limits the precision of comparisons and scenario estimates.
Bottom Line
Investment Verdict: NEUTRAL
Revvity’s latest EPS beat, positive reported earnings growth, and free cash flow provide constructive evidence, but modest revenue growth, low ROE, debt, and a high trailing P/E temper the picture. The analyst consensus and target datasets are mixed, so the central question is whether future earnings estimates are supported by durable sales growth and cash generation, not simply by one quarter’s beat.
Action Items for Investors
- Long-term investors: Track revenue growth, margins, recurring consumables demand, and cash conversion across multiple reports; the current information does not settle whether recent earnings growth is sustainable.
- Short-term traders: Treat $151 to $160 as a near-term reference range based on Friday’s session, and remember U.S. markets reopen Monday, November 16. The supplied data do not include enough volume or indicator history to validate a technical signal.
- Risk management: Account for the spread between analyst target sets, the high trailing valuation, and net debt. Scenario ranges are analytical references, not price predictions or personalized guidance.
What to Watch This Week
- Any detailed Investor Day presentation or follow-up that clarifies strategy, financial objectives, or portfolio priorities.
- Trading and price behavior after the weekend, with U.S. markets reopening Monday, November 16.
- Updates to analyst estimates and target coverage, especially whether the conflicting target datasets converge around a common outlook.
Disclosure: This report is for informational purposes only and is not investment advice. It does not recommend buying, selling, or holding any security. Analyst ratings and targets are third-party opinions and can change.
Sources
Share this report
Share this article
Spread the word on social media
Think RVTY will outperform? Prove it.
Free practice contests — earn Alpha CoinsExplore More Content
Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.
Spotted something wrong? Report an error.